Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 11/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17819313 | 0.87 | ELANE (0.39) | ELANECTSKCYP2C9 | |
| SCHEMBL17819329 | 0.84 | ELANE (0.50) | ELANECTSKCYP2C9CYP3A4NOTUM | |
| SCHEMBL17819368 | 0.81 | ELANE (0.41) | ELANECTSKALDH1A1CYP2C9CYP3A4 | |
| SCHEMBL17819346 | 0.77 | ELANE (0.51) | ELANECTSKCYP2C9CYP3A4NOTUM | |
| SCHEMBL17964358 | 0.77 | ELANE (0.47) | ELANECTSKCYP2C9CYP3A4NOTUM | |
| SCHEMBL17992472 | 0.76 | KDM4E (0.36) | ALDH1A1POLB | |
| SCHEMBL17819296 | 0.76 | ELANE (0.50) | ELANECTSKCYP2C9CYP3A4NOTUM | |
| SCHEMBL17819304 | 0.76 | ELANE (0.62) | ELANECTSKCYP2C9CYP3A4NOTUM | |
| SCHEMBL21828992 | 0.74 | ELANE (0.47) | ELANECTSKCYP2C9CYP3A4 | |
| SCHEMBL17819328 | 0.73 | ELANE (0.46) | ELANECTSKCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168101-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168101-A1 | NOVEL COMPOUNDS | ELANE, SERPINB1, MPO | ELANE 1/4885CTSK 46/4885ALDH1A1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.